Skip to main content
. 2023 Oct 17;55(2):2268535. doi: 10.1080/07853890.2023.2268535

Table 1.

Demographic, baseline physical exam and previous SARS-CoV-2 infection in the study groups.

Variables Total patients (n = 173)
Placebo (n = 86)
Domperidone (n = 87)
p value
N (%) Mean (SD) N (%) Mean (SD) N (%) Mean (SD)
Gender              
 Male 64 (37)   33 (38.4)   31 (35.6)   0.709
 Female 109 (63)   53 (61.6)   56 (64.4)  
Age (years)   47.8 (1.2)   47.7 (1.7)   47.8 (1.6)  
Race              
 Caucasian 154 (89)   74 (86)   80 (92)   0.431
 Black 1 (0.6)   1 (1.2)   0  
 Hispanic 17 (9.8)   10 (11.6)   7 (8)  
 Asiatic 1 (0.6)   1 (1.2)   0  
Body mass index (kg/m2)   26 (0.4)   26.6 (0.6)   25.5 (0.5) 0.323
Systolic BP (mmHg)   124.6 (1)   124.4 (1.5)   124.7 (1.3) 0.890
Diastolic BP (mmHg)   76.7 (0.8)   76.4 (1.1)   77 (1) 0.719
Respiratory rate (breaths/min)   15.9 (0.4)   15.6 (0.4)   16.3 (0.8) 0.389
Oxygen saturation (%)   97.2 (0.1)   97.1 (0.1)   97.3 (0.1) 0.318
Heart rate (beats/min)   81.8 (1)   83.1 (1.5)   80.6 (1.3) 0.306
Axillary temperature (°x)   36.4 (0.1)   36.5 (0.1)   36.4 (0.1) 0.788
Previous COVID-19 infection              
 No 146 (84.4)   73 (84.9)   73 (83.9)   0.860
 Yes 27 (15.6)   13 (15.1)   14 (16.1)  
Severity of previous COVID-19 infection              
 Asymptomatic 1 (3.7)   1 (7.7)   0    
 Mild 17 (63)   10 (76.9)   7 (50)  
 Moderate 8 (29.6)   2 (15.4)   6 (42.9)  
 Severe 1 (3.7)   0   1 (7.1)  
Time from previous SARS-CoV-2 infection (months)   14.2 (1.7)   12.6 (2.6)   15.8 (2.1) 0.342

SD: standard deviation.